Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556882 | 1.00 | SIRT2 (0.38) | SIRT2PTPN1HSD17B10PDCD1CD274 | |
| SCHEMBL13256759 | 0.83 | SIRT2 (0.38) | SIRT2CYP3A4TDP1IDO1ALDH1A1 | |
| SCHEMBL21733183 | 0.80 | ALDH1A1 (0.40) | SIRT2CYP3A4CYP1A2CYP2D6TDP1 | |
| SCHEMBL20354954 | 0.78 | APP (0.45) | SIRT2TDP1LMNAMEN1GAA | |
| SCHEMBL30657526 | 0.78 | PGK1 (0.39) | SIRT2LMNAPGK1 | |
| SCHEMBL21539326 | 0.78 | CCNE2 (0.39) | SIRT2CYP1A2CYP2C19LMNAMEN1 | |
| SCHEMBL1978195 | 0.78 | PGK1 (0.39) | SIRT2LMNAPGK1 | |
| SCHEMBL16261557 | 0.76 | LRRK2 (0.37) | SIRT2HSD17B10PDCD1CD274CYP3A4 | |
| SCHEMBL4861825 | 0.76 | NOS3 (0.38) | PTPN1HSD17B10CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL94534 | 0.76 | NCF1 (0.43) | CYP3A4CYP1A2CYP2C19LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250339494-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | UNIV PARIS CITE (FR) | 2025-11-06 | — | — | US | disclosed |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4219487-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2012174199-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174199-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2011156245-A2 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156245-A2 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011109277-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109277-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011034741-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011034741-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2007015877-A2 | INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015877-A2 | INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | SIRT2 570/4885PTPN1 1220/4885HSD17B10 2789/4885 |
| US-20250339494-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | IL2, CXCL10, IFNG | SIRT2 1976/4885PTPN1 3516/4885HSD17B10 931/4885 |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | SIRT2 570/4885PTPN1 1220/4885HSD17B10 2789/4885 |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | SIRT2 560/4885PTPN1 1138/4885HSD17B10 2716/4885 |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | SIRT2 560/4885PTPN1 1138/4885HSD17B10 2716/4885 |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | SIRT2 570/4885PTPN1 1220/4885HSD17B10 2789/4885 |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | SIRT2 570/4885PTPN1 1220/4885HSD17B10 2789/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | SIRT2 271/4885PTPN1 1829/4885HSD17B10 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.